A global phase 1/2 study reported that ALK-positive NSCLC patients treated with lorlatinib after alectinib had a median PFS of 5.5 months in all patients and 9.2 months in Japanese patients [18,19]. Here, ALK is linked to non-small cell lung carcinoma.